共 50 条
- [21] Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM)BLOOD, 2017, 130Cohen, Adam D.Garfall, Alfred L.Stadtmauer, Edward A.Lacey, Simon F.Lancaster, EricVogl, Dan T.Weiss, Brendan M.Ambrose, David E.Nelson, Anne MarieChen, FangPlesa, GabrielaKulikovskaya, IrinaGonzalez, VanessaGupta, MinnalYoung, Regina M.Dengel, KarenO'keefe, LauraLe, SamanthaRichardson, CelesteIsaacs, Randi E.Melenhorst, J. JosephLevine, Bruce L.June, Carl H.Milone, Michael C.
- [22] A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myelomaJournal of Hematology & Oncology, 14Heng MeiChenggong LiHuiwen JiangXinying ZhaoZhiping HuangDan JinTao GuoHaiming KouLin LiuLu TangPing YinZhihui WangLisha AiSha KeYimeng XiaJun DengLei ChenLi CaiChunyan SunLinghui XiaGaoquan HuaYu Hu
- [23] A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myelomaJOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)Mei, HengLi, ChenggongJiang, HuiwenZhao, XinyingHuang, ZhipingJin, DanGuo, TaoKou, HaimingLiu, LinTang, LuYin, PingWang, ZhihuiAi, LishaKe, ShaXia, YimengDeng, JunChen, LeiCai, LiSun, ChunyanXia, LinghuiHua, GaoquanHu, Yu
- [24] Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Multiple MyelomaTRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (01): : 118.e1 - 118.e15Yamamoto, ChihiroMinakata, DaisukeYokoyama, DaizoFuruki, ShukaNoguchi, AtsutoKoyama, ShunsukeOyama, TakashiMurahashi, RuiNakashima, HirotomoIkeda, TakashiKawaguchi, Shin-ichiroHyodo, KazukiToda, YumikoIto, ShokoNagayama, TakashiUmino, KentoMorita, KaoruAshizawa, MasahiroUeda, MasuzuHatano, KaoruSato, KazuyaOhmine, KenFujiwara, Shin-ichiroKanda, Yoshinobu
- [25] Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myelomaANNALS OF MEDICINE, 2021, 53 (01) : 1547 - 1559Zhang, LinaShen, XuxingYu, WenjunLi, JingZhang, JueZhang, RunLi, JianyongChen, Lijuan
- [26] Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapyBLOOD ADVANCES, 2022, 6 (07) : 2045 - 2054Kambhampati, SwethaSheng, YingHuang, Chiung-YuBylsma, SophiaLo, MimiKennedy, VanessaNatsuhara, KelseyMartin, ThomasWolf, JeffreyShah, NinaWong, Sandy W.
- [27] P-BCMA-ALLO1-A Fully Allogeneic Stem Cell Memory T Cell (TSCM) CAR-T Therapy Targeting BCMA for the Treatment of Multiple Myeloma Shows Potent Anti-Tumor ActivityMOLECULAR THERAPY, 2021, 29 (04) : 382 - 383Richter, MaximilianCranert, StaceyPatil, DeepakZhang, YanTan, YeningTong, MinDomingo, ChristineWeiss, LeslieMarquez, KarlSparks, JessicaArgus, ElviraMartin, ChristopherOstertag, EricJain, SumitiCoronella, JuliaShedlock, Devon
- [28] Efficacy of teclistamab in patients (pts) with heavily pretreated, relapsed/refractory multiple myeloma (RRMM), including those refractory to penta RRMM and BCMA (B-cell maturation antigen) directed therapy (BDT)JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Venkatesh, PriyankaAtrash, ShebliPaul, BarryAlkharabsheh, OmarAfrough, AimazMahmoudjafari, ZahraMushtaq, Muhammad UmairHashmi, HamzaDavis, James A.Abdallah, Al-Ola A.
- [29] Preclinical assessment of LCAR-B38M, a novel BCMA-targeting chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory multiple myelomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E160 - E160Fan, XiaohuZhuang, QiuchuanYang, LeiHao, JiayingZhao, DanZhao, YunchengWang, PingyanGeng, Dong
- [30] Clinical outcomes of patients with multiple myeloma following disease progression after BCMA-targeted CAR T-cell therapyJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Subramanian, Naveen G.Pleitez, Hector GarciaPasvolsky, OrenKalariya, NileshPatel, Krina K.Ferreri, Christopher J.